Rajiv I. Modi

Biography

 Dr. Modi joined Novavax’ Board in April 2009 and represents Satellite Overseas (Holdings) Limited, one of Novavax’ largest shareholders. He has been the Managing Director of Cadila Pharmaceuticals. Ltd., a company organized in India, since 1995 and is Director of other Cadila Group companies. Dr. Modi holds a Ph.D. in Biological Science from the University of Michigan, Ann Arbor, USA. He obtained his M.Sc. in Biochemical Engineering from Indian Institute of Technology (IIT), Bombay, India. Dr. Modi is the winner of the Genetic Society of America’s Best Scientific Poster at the International Genetics Congress held in August 1988 by the Genetic Society of America. He has presented many papers on various aspects of Chemical Engineering, Biochemical Engineering and Biotechnology at many institutes in India and abroad and is a member of many prestigious organizations and associations.

Research Interest

Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Our vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis.